Long-term Follow-up After Conversion from Intravenous Epoprostenol to Oral Therapy With Bosentan or Sildenafil in 13 Patients With Pulmonary Arterial Hypertension
Authors:
- James E. LoydJLJames E. Loyd
- Amy L. MullicanAMAmy L. Mullican
- Cynthia A. FinkCFCynthia A. Fink
- Ivan M. RobbinsIRIvan M. Robbins
- 1 April 2007
- journal article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 26 (4) , 363-369
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Outcome in 91 Consecutive Patients with Pulmonary Arterial Hypertension Receiving EpoprostenolAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Survival in Primary Pulmonary HypertensionCirculation, 2002
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJACC, 2002
- Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of DiseaseAnnals of Internal Medicine, 2000
- Epoprostenol for Treatment of Pulmonary Hypertension in Patients With Systemic Lupus ErythematosusChest, 2000
- Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case SeriesAnnals of Internal Medicine, 1999
- Long-Term Prostacyclin for Pulmonary Hypertension With Associated Congenital Heart DefectsCirculation, 1999
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996